| INTRODUCTION
People with haemophilia A (HA) or haemophilia B (HB) may develop inhibitors, which are antibodies that interfere with the function of the factor VIII (FVIII) or factor IX (FIX) products with which they are treated. Such antibodies occur as a natural process when the immune system does not recognize the normal clotting factor used for treatment, because the individual produces no clotting factor or produces only a structurally abnormal protein. 1, 2 Inhibitors act by combining with the factor and either blocking its action in clotting or removing it from the circulation. Inhibitors, by definition, interfere with or "neutralize" clotting factor activity. Anti-FVIII or anti-FIX antibodies that do not interfere with clotting factor function may also be present; these have been called "non-neutralizing" or "non-inhibitory" antibodies. [3] [4] [5] Thus, antidrug antibodies occurring in haemophilia may or may not interfere with clotting function, and not all are correctly termed "inhibitors." FVIII or FIX inhibitors may also occur in individuals without haemophilia as part of an autoimmune process. 6 Inhibitors in haemophilia are of clinical significance when they require alteration of the patient's treatment regimen. The most significant inhibitors show an anamnestic response to factor infusion and require the use of by-passing agents to achieve haemostasis and/ or immune tolerance induction (ITI) therapy to eliminate the inhibitor. 7, 8 Some FIX inhibitors may produce a dangerous anaphylactic response. 9, 10 Non-anamnestic inhibitors may persist at a low level, allowing treatment with larger doses of factor products. Other inhibitors, termed "transient," disappear spontaneously within 6 months.
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The long-term presence of an inhibitor increases both morbidity 12 and mortality 13 in haemophilia patients. At first detection, it may not be possible to determine which kind of inhibitor is present, and close 
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peptide between the B and A3 domains. 2, 16 FVIII is released from VWF and the B-domain is removed upon its activation to FVIIIa, the cofactor that facilitates the junction of activated factor IX (FIXa) and factor X on the phospholipid membrane to produce activated factor X (FXa). 16 Conventional treatment products for HA have included recombinant full-length FVIII, recombinant FVIII with the B-domain deleted, plasma-derived purified FVIII and plasma-derived FVIII with VWF. Products have recently come to market that have been modified to increase half-life by PEGylation or by fusing FVIII to the Fc portion of immunoglobulins or to albumin. 17 A novel FVIII-mimetic drug, Hemlibra ® (emicizumab), which has recently been approved for use in FVIII inhibitor patients in the USA, is a bivalent antibody that substitutes for FVIIIa in the production of FXa. 18 It may be used to treat patients with inhibitors, because it does not contain FVIII. Other by-passing agents used to treat patients with inhibitors contain activated clotting factors that by-pass FVIII in the clotting cascade; these include recombinant factor VIIa and activated prothrombin complex concentrates (FEIBA). 19 FIX is a vitamin K-dependent protease with a mature protein length of 415 amino acids, organized into a gamma-glutamic acid (GLA) do- (Table 1A) . 26 FIX inhibitors are also predominately of IgG 4 subclass, with other subclasses seen less frequently (Table 1B) . [27] [28] [29] T A B L E 1 Anti-factor VIII (A) and anti-factor IX (B) immunoglobulins (Ig) by fluorescence immunoassay among haemophilia patients negative or positive by modified Nijmegen-Bethesda assay (NBA) compared to healthy donors (% positive). Adapted from 26, 29 and it is unclear how they may affect functional inhibitor assays and whether the affinity and kinetic differences observed in vitro reflect differences in inhibitor action in vivo.
FIX inhibitors are most often directed against the GLA or protease domains. 49 Their kinetics have been only minimally studied. produce results equivalent to plasma. 50 Porcine FVIII has been substituted as the FVIII source to detect inhibitors that cross-react with that product. 51 The amount of factor activity remaining in the patient mixture divided by the activity of the control mixture, multiplied by 100, gives the % residual activity (RA), which is converted to arbitrary units For FIX inhibitors, one-stage clotting is most commonly used. Strong inhibitors must be diluted prior to testing, introducing the additional variables of diluent and dilution scheme. became the "gold standard" for inhibitor testing. 54 In 2012, CDC investigators validated a previously proposed modification to the NBA using preanalytical heat treatment (PHT) of patient plasma to remove factor, which allows accurate testing of patients recently treated or on prophylaxis or ITI with conventional FVIII or FIX products. 40 This 40 in italics CDC-modified NBA (CDC-NBA), performed as shown in Figure 1 , has been used to test for both FVIII and IX inhibitors.
| INHIBITOR MEASUREMENT METHODS
| Clot-based functional assays
F I G U R E 1
| Chromogenic functional assays
Inhibitor tests using factor assays that have the endpoint of clot formation have certain limitations. The formation of a fibrin clot relies on many variables and may be inhibited by unfractionated heparin (UFH) from central lines or ports, 55 LA 56 and non-specific inhibitors of coagulation common in children. 57 It is often difficult to distinguish this inhibition of clotting from a true factor inhibitor. Because tests for FVIII using chromogenic substrates have a more specific endpoint, cleavage of factor Xa, their use in inhibitor testing was proposed by Blanco et al. 58 Chromogenic factor assays also have the advantage of increased precision. 59 A chromogenic Bethesda assay (CBA), identical to the CDC-NBA except for use of a chromogenic factor assay to measure the FVIII endpoint, has been described. 
| Antibody detection assays
Methods developed to detect antibodies to FVIII and FIX include the enzyme-linked immunosorbent assay (ELISA), [63] [64] [65] immunoprecipitation assay (IP), 66 fluorescence immunoassay (FLI) 60, 67, 68 and surface plasmon resonance assay. 69 Because they measure both inhibitory and non-inhibitory antibodies, they are not equivalent to and cannot be substituted for functional inhibitor assays. They may be used to screen specimens for those requiring inhibitor assays 65 or to confirm the presence of specific antibodies. 60, 70, 71 
| RECENT ASSAY MODIFICATIONS
| Preanalytical heat treatment
Patients undergoing prophylactic or ITI therapy or being treated for a bleeding episode may have FVIII or FIX circulating continuously.
Failure to account for this factor in performance of the BA or NBA may produce a false-negative test, unless a relatively high-titre inhibitor is present, by causing RA to be 100% or higher leading to an NBU of 0. This is sometimes accounted for by adding half of the patient's factor level to the activity of the control mixture before calculating the RA. 74 It has not been documented, however, that this modification allows detection of low-titre inhibitors, which may be complexed with the infused factor. 34 Table 2 . 78 It also adds significantly to the time for performance of inhibitor tests. Heating to 56° for 30 minutes, followed by centrifugation, has been shown to reduce both FVIII activity and FVIII antigen to <1 unit/decilitre and to result in changes in NBA results. 40 Among 202 specimens with negative results before heating, 3% showed a change to positive after heating, including 1% of those from patients with no history of inhibitor and 17% of those with previous positive inhibitors. The value of PHT of specimens in revealing low-titre FVIII inhibitors is greater in patients undergoing ITI 79 and those with acquired haemophilia. 70 The latter study showed a 10-fold increase in detection of acquired inhibitors after heating; however, using the more vigorous heating method, it also documented some 
| Identification of false-positive results
The finding that more than 25% of specimens with inhibitor titres of 0.5-1.9 NBU lack anti-FVIII antibodies has led to the suggestion that inhibitor results in that range be confirmed with more specific tests. 60, 71 Testing with the CBA confirms that the inhibition of clotting observed is specific to FVIII and not the result of a LA, UFH contamination or a non-specific inhibitor. 58, 59 The absence of specific anti-FVIII 
| Reagent substitutions
Adoption of the NBA has met barriers in some clinical laboratories, due to the increased cost of FVIIIDP over buffer as diluent and the lack of commercial availability of appropriate reagents. Some reagent substitutions have been evaluated. A small study found that substitution of immunodepleted FVIIIDP from two manufacturers for naturally deficient FVIIIDP in the control mixture produced significant differences in inhibitor titres; the authors suggested that this might be due to either lack of VWF or the presence of preparatory antibodies in the FVIIIDP. 82 Chemically depleted FVIIIDP was also found to be problematic. The key ISTH study of the NBA, however, used immunodepleted FVIIIDP, also recommending that chemically depleted FVIIIDP not be used due to the possible presence of FVIII fragments. 54 A multi-laboratory study demonstrated differences, primarily when the immunodepleted FVIIIDP was used to dilute specimens. 83 Because non-plasma diluents have been successfully substituted for FVIIIDP, it seems unlikely that lack of VWF is the key variable. The presence of contaminating antibodies in some FVIIIDP preparations seems more likely. A conclusive study comparing multiple sources of FVIIIDP has not been conducted. This reagent, however, is a potential source of inter-laboratory variability and may not be necessary if nonplasma reagents can be substituted.
Substitution of 4% bovine serum albumin (BSA) for FVIIIDP in the NBA as a cheaper and more uniform option was originally reported to be satisfactory in a small number of specimens. 84 This was confirmed by Kershaw et al 85 in a larger study. Use of imidazole buffer alone, as in the original BA, has also been supported. 83 The efficacy of different diluents in the CDC-NBA was evaluated in 326 specimens, using 4% BSA, imidazole-buffered BSA or imidazole buffer alone. All could be successfully substituted for FVIIIDP in the control mixture, with 4% BSA providing sensitivity of 97% and specificity of 99% compared to FVIIIDP. 86 Non-plasma diluents provided greater stability of FVIII activity during incubation than did FVIIIDP (Figure 2 ). 86 A similar stability comparison showed that HEPES-buffered and unbuffered NPP were inferior to imidazole-buffered NPP at maintaining both FVIII and pH stability. 86 Comparison of the many commercial buffered NPP reagents has not been reported. Any reagent substitution used in the NBA or the BA must be validated; it cannot be assumed that reagents suitable for other purposes can withstand the 2 hours at 37°C required for these assays. Also, substitutions may alter assay performance: use of BSA required that the threshold for positivity of T A B L E 2 Per cent (%) of baseline anti-factor VIII IgG 4 remaining after preanalytical heat treatment of plasma from haemophilia patients with given Nijmegen-Bethesda units (NBU), measured by fluorescence immunoassay in median fluorescence intensity (MFI) the CDC-NBA be raised from ≥0.5 to ≥0.6 NBU to achieve the same results, as discussed below. 86 
| Definition of assay positivity
The Scientific and Standardization Committee of the ISTH has recommended that a FVIII inhibitor test by NBA be considered positive if the results are ≥0.6 NBU. 11 The definitive paper validating the NBA, however, used ≥0.5 NBU. 54 Analysis suggests that the threshold for positivity for these, as for other clinical tests, is method-specific. Using the CDC-NBA, results on over 600 specimens from patients with negative or positive history of an inhibitor suggested that a threshold of ≥0.5
NBU was appropriate for that method. 40 Comparison of results of the CDC-NBA with the presence of anti-FVIII IgG 4 antibodies showed that the presence of such antibodies increased from 14% at 0.4 NBU to 67% at 0.5 NBU, confirming that threshold (Figure 3) . 87 For FIX inhibitor tests using the CDC-NBA, a threshold of ≥0.3 NBU was established using more than 200 specimens. 40 Comparison 
| Inhibitor calculations
Most automated analysers cannot be programmed to calculate %RA and NBU; however, simple statistical programs in database software or on calculators can be used for that purpose to assure that results are calculated correctly and avoid errors in graph reading. The formulas used are as follows: %RA = (factor level of patient + NPP mix/factor level of diluent + NPP mix) × 100, and NBU = (2-log %RA)/0.301. 52 If testing of the undiluted patient plasma gives 25%-100% RA, then the original result is used. If it produces a result of <25% RA (>2.0 NBU), dilution of the patient plasma is required to achieve a %RA between 25% and 75% for accurate quantitation. NBU is then multiplied by the dilution factor to calculate a final NBU for reporting (Table 3) (Table 3) . Multiplication by a large dilution factor, however, magnifies small errors, and even acceptable variation in the performance of the factor assays can result in differences between dilutions and between different assays when multiplied by 10 or higher. Inhibitors with Type 2 kinetics show similar %RA at multiple dilutions, which can result in progressively higher inhibitor results with multiplication by dilution factors (Table 3) . It is usually recommended to report the dilution having RA closest to 50%; however, some laboratories prefer to use the first dilution falling below 75% RA to avoid error introduced by use of larger multiplication factors. For monitoring change in titre over time, it may be most useful to follow the same dilution in each subsequent assay to detect rise or fall in the NBU.
The original publication on the BA recommended that positive specimens be read from the curve with RA between 25% and 75% and stated that results with 75%-100% RA might require "more sensitive methods"
for the detection of low-titre inhibitors. 52 This has been interpreted to mean that inhibitors in that range cannot be accurately quantitated. 88 Using today's assays ( Figure 5 ), it can be demonstrated that when known FVIII inhibitors are diluted, the curves are linear and have a negative slope between 75 and 100% RA, suggesting that inhibitor titres in this range (<0.4 NBU) can be quantitated. 87 These curves, however, do not cross the Y-axis at 0 NBU, indicating that the titre cannot be accurately detected below a limit, which for the CDC-NBA has been calculated to be 0.2 NBU. This was consistent with the finding that inhibitor titres in healthy individuals have a mean + 3 standard deviations of 0.17, indicating a limit of detection (LOD) of 0.2 NBU. 87 It is most accurate to report quantitative results from assays only for inhibitors equal to or greater than the LOD and to report lower results as less than the LOD. Inhibitors in the range between the LOD and the threshold for positivity, however, may be reported and in some cases, appear to be clinically significant. 87 
| QUALITY CONTROL
Most published methods do not address the issue of quality control for inhibitor assays. Inter-laboratory variation has been documented to be large by proficiency testing and external quality assessment programs worldwide. Coefficients of variation (CVs) as high as 50%
and false-positive rates up to 32% have been seen on distributed F I G U R E 2 Stability of factor VIII activity in imidazole-buffered normal pooled plasma in a 1:1 mix with factor VIII-deficient plasma (FVIIIDP), 4% bovine serum albumin (BSA), imidazole-buffered BSA (IB-BSA) or imidazole buffer (IB) during 120-minute incubation at 37°C. Mean of duplicate determinations on triplicate specimens. IU/dL = International Units per decilitre 86 specimens. 88, 89 It is likely that differences in methods and reagents contribute to this variability among well-qualified laboratories. 88 Among North American laboratories surveyed by the North American Specialized Coagulation Laboratory Association, 20% reported using the Nijmegen method, 10% the Bethesda assay and 70% a combination of components best described as a hybrid assay. 88, 90 Many reported using multiple vendors for reagents such as NPP.
Careful internal quality control, as used for other clinical tests, must be applied to inhibitor tests as well and has been shown to produce acceptable intra-laboratory reproducibility. Analytical variables playing a role in inter-laboratory variability include differences in key reagents, such as NPP, FVIIIDP and diluent; dilutions used for strong inhibitors 91 ; incubation method; and controls.
There have been only a few studies validating individual commercial reagents for suitability in inhibitor assays, discussed above. There has been no evidence that use of different instruments or reagents for clotting factor measurement as the endpoint determination for inhibitor assays influences results with conventional products. Comparison of 3 APTT reagents with a modified FIX product found no effect on the inhibitor results, when a heating step was used. 41 If products are adequately removed by PHT, then only the added NPP will be measured in the test, and reagent differences should not affect the results.
Factor measurement for inhibitor assays should be performed using a calibrator related to an international standard for FVIII and FIX, to produce consistency of results over time and allow use of published reference ranges.
Attempts to establish an international standard for inhibitor assays have been unsuccessful. To provide two levels of controls, use of a known inhibitor plasma diluted in FVIIIDP to a level of 1 NBU as a positive control and monitoring of the FVIII activity of the control mixture as the negative control has been suggested. 40 Using the CDC-NBA, the CV of the negative control was found to be 9.8% (n = 117) and 
| PREANALYTICAL ISSUES
Preanalytical variables important for inhibitor assays include presence in the specimen of UFH or other contaminating substances, LA, non-specific inhibitors of coagulation and infused or endogenous factor. 92 Appropriate clinical information must be collected to assess for these variables, including whether the specimen was collected from a port or central line flushed with UFH and any treatment product that might be present in the specimen. If PHT is used, it is not considered necessary to ask the patient to refrain from treatment to "wash out"
the factor prior to testing with conventional treatment products. Information on the effects of by-passing agents and longer-acting products on inhibitor assays is incomplete and is discussed below. If UFH is present, the specimen may be treated to remove it prior to testing, or a CBA can be used. 55 Presence of other anticoagulant drugs could also influence test results. While measurement of postinfusion factors levels with some products is influenced by the APTT reagent used, that is not expected to be the case for inhibitor assays using PHT, as removal of treatment products with PHT leaves only the added NPP to be measured, not the product or patient's factor. That appears to be the best course of action for laboratories in dealing with patients on multiple products; however, validation for each product that the PHT method used adequately removes both functional and immunologic reactivity is required. Few such studies have been reported, some using spiked specimens which may not be equivalent to patient plasmas. To date, the most significant problem noted has been with the FVIII-mimetic Hemlibra ® (emicizumab). That drug, which is an antibody and cannot be removed by PHT, interferes with inhibitor measurement in clot-based assays; however, because it does not react with bovine factors, a bovine chromogenic assay can be used. 80 An example of results on a patient receiving Hemlibra ® during clinical trials is shown in Table 4 with both assay types. Conversely, pharmacokinetic studies are also recommended for those with poor response to therapy and negative inhibitor titres. 15 It is not clear that all antibodies that can combine with factor and remove it from the circulation will be detected in vitro as inhibitors. 
| MONITORING OF IMMUNE TOLERANCE INDUCTION (ITI) THERAPY
| INTERPRETATION OF INHIBITOR TEST RESULTS
Laboratory
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